New EASD analyses, not yet peer reviewed, found about 13 to 14% weight loss at the 36 mg dose and an indirect edge over high-dose oral semaglutide in diabetes.
Recap by typeshit. Full story at Medical News Today.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
The Phase III trial tested Lilly's once-weekly triple receptor agonist for efficacy and safety in people with obesity and type 2 diabetes.
The Swiss drugmaker is taking on the Chinese biotech's investigational obesity drug, Reuters reports, adding to the rush of big pharma obesity deals.
Loading…